Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis
阐明 LYST 介导的组织工程血管移植狭窄的分子机制
基本信息
- 批准号:10378148
- 负责人:
- 金额:$ 66.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAutologousAutomobile DrivingBiocompatible MaterialsBlood Vessel ProsthesisBlood VesselsCHS1 geneCardiac Surgery proceduresCardiovascular systemCause of DeathCell physiologyCellsChildClinicalClinical ResearchClinical TrialsCodeComplicationComputer ModelsCongenital AbnormalityCongenital Heart DefectsDevelopmentEndothelial CellsGoalsGrowthImmuneImmune responseImmunosuppressionImplantIn VitroIncidenceInfiltrationInflammationLive BirthMediatingMedicalMessenger RNAMicroRNAsModelingMolecularMorbidity - disease rateMusMutant Strains MiceMutationNewborn InfantOperative Surgical ProceduresParacrine CommunicationPostoperative PeriodProceduresProcessProductionProteinsPublic HealthRegulator GenesRoleSafetySerious Adverse EventSignal TransductionSmooth Muscle MyocytesSourceStenosisSurgical complicationSystemTamoxifenTherapeuticTissue EngineeringTransgenic OrganismsTubular formationVascular GraftVesicleWild Type Mousebasecell typecongenital heart disordercostcritical perioddesigndisabilityextracellular vesiclesfunctional restorationgenetic regulatory proteingraft functionheart valve replacementimmunoregulationimplantationimprovedimproved outcomein vivomacrophagemanmortalitymouse modelmutantnext generationnoveloperationpreventrational designreconstructionrepairedscaffoldvascular tissue engineering
项目摘要
PROJECT SUMMARY
Tissue engineering provides a strategy for developing better biomaterials for use in congenital heart surgery.
Results of our clinical trials evaluating the use of tissue engineered vascular grafts (TEVGs) in congenital heart
surgery have demonstrated the growth capacity of the TEVG making it the first man made graft with growth
potential. However, results of these trials have also revealed that stenosis is the most common graft-related
complication and the principle hurdle preventing its widespread clinical use. Recently, we have identified a novel
immune-regulatory protein encoded by the LYST gene. Mutations of the LYST gene dramatically reduce the
incidence of TEVG stenosis in murine models. In this proposal, we will investigate the cellular and molecular
mechanisms underlying the formation of LYST-mediated TEVG stenosis. We will use a on-demand inducible
LYST-mutant mouse to determine the critical temporal factors underling this process. Next, we will use a
conditional LYST-mutant model to elucidate the roles of macrophages and determine the critical cell type(s)
responsible for driving LYST-mediated TEVG stenosis. Finally, we will evaluate the role of extracellular vesicle-
dependent intercellular signaling on the formation of LYST-mediated TEVG stenosis. Successful completion of
these studies would open the door to rationally designing strategies to inhibit the formation of TEVG stenosis
based on modulating LYST function. The development of an improved TEVG with growth capacity has the
potential to improve outcomes for children born with congenital heart disease.
项目摘要
组织工程为开发更好的用于先天性心脏病手术的生物材料提供了一种策略。
评价组织工程血管移植物(TEVG)在先天性心脏病中应用的临床试验结果
手术已经证明了TEVG的生长能力,使其成为第一个人造移植物,
潜力然而,这些试验的结果也表明,狭窄是最常见的移植物相关性
并发症和阻碍其广泛临床应用的原则障碍。最近我们发现了一本小说
由LYST基因编码的免疫调节蛋白。LYST基因的突变显著降低了
小鼠模型中TEVG狭窄的发生率。在本提案中,我们将研究细胞和分子
LYST介导的TEVG狭窄形成的潜在机制。我们将使用按需诱导
LYST突变小鼠,以确定该过程的关键时间因素。接下来,我们将使用
阐明巨噬细胞作用并确定关键细胞类型的条件性LYST突变体模型
负责驱动LYST介导的TEVG狭窄。最后,我们将评估细胞外囊泡的作用-
依赖于细胞间信号传导的LYST介导的TEVG狭窄的形成。成功完成
这些研究将为合理设计抑制TEVG狭窄形成的策略打开大门
基于调节LYST功能。具有增长能力的改进的TEVG的开发具有
改善先天性心脏病患儿预后的潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
christopher Kane breuer其他文献
christopher Kane breuer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('christopher Kane breuer', 18)}}的其他基金
A Preclinical Study Evaluating and Comparing the Efficacy of Tissue Engineered Vascular Grafts to Polytetrafluoroethylene Grafts
评估和比较组织工程血管移植物与聚四氟乙烯移植物功效的临床前研究
- 批准号:
10420151 - 财政年份:2022
- 资助金额:
$ 66.86万 - 项目类别:
A Preclinical Study Evaluating and Comparing the Efficacy of Tissue Engineered Vascular Grafts to Polytetrafluoroethylene Grafts
评估和比较组织工程血管移植物与聚四氟乙烯移植物功效的临床前研究
- 批准号:
10645005 - 财政年份:2022
- 资助金额:
$ 66.86万 - 项目类别:
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis
阐明 LYST 介导的组织工程血管移植狭窄的分子机制
- 批准号:
10599990 - 财政年份:2021
- 资助金额:
$ 66.86万 - 项目类别:
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis
阐明 LYST 介导的组织工程血管移植狭窄的分子机制
- 批准号:
10552387 - 财政年份:2021
- 资助金额:
$ 66.86万 - 项目类别:
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis
阐明 LYST 介导的组织工程血管移植狭窄的分子机制
- 批准号:
10806468 - 财政年份:2021
- 资助金额:
$ 66.86万 - 项目类别:
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis
阐明 LYST 介导的组织工程血管移植狭窄的分子机制
- 批准号:
10806469 - 财政年份:2021
- 资助金额:
$ 66.86万 - 项目类别:
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis
阐明 LYST 介导的组织工程血管移植狭窄的分子机制
- 批准号:
10182308 - 财政年份:2021
- 资助金额:
$ 66.86万 - 项目类别:
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis
阐明 LYST 介导的组织工程血管移植狭窄的分子机制
- 批准号:
10579691 - 财政年份:2021
- 资助金额:
$ 66.86万 - 项目类别:
A Study Evaluating the Safety and Efficacy of Second-Generation Tissue Engineered Vascular Grafts (TEVG2)
评估第二代组织工程血管移植物 (TEVG2) 安全性和有效性的研究
- 批准号:
10363610 - 财政年份:2019
- 资助金额:
$ 66.86万 - 项目类别:
A Study Evaluating the Safety and Efficacy of Second-Generation Tissue Engineered Vascular Grafts (TEVG2)
评估第二代组织工程血管移植物 (TEVG2) 安全性和有效性的研究
- 批准号:
10705412 - 财政年份:2019
- 资助金额:
$ 66.86万 - 项目类别:
相似海外基金
Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
- 批准号:
MR/Y019458/1 - 财政年份:2024
- 资助金额:
$ 66.86万 - 项目类别:
Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
- 批准号:
2897580 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
- 批准号:
10658324 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
- 批准号:
10794761 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
- 批准号:
2304430 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
Cooperative Agreement
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
- 批准号:
MR/X00466X/1 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
Fellowship
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
- 批准号:
23K15543 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
- 批准号:
10976161 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
- 批准号:
10720234 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别:
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
- 批准号:
10721983 - 财政年份:2023
- 资助金额:
$ 66.86万 - 项目类别: